fbpx

Day

September 8, 2020
Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and acute pyelonephritis Well-tolerated with comparable safety profile to intravenous ertapenem Spero intends to complete NDA submission for U.S. regulatory approval of tebipenem HBr in the second quarter of 2021 Management to host...

News

DNA analysis of 442 Viking skeletons rewrites the story of Viking culture
16. September 2020
Hope that a brain injection could cure type 2 diabetes
7. September 2020
Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge